BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 58775.5% from a year ago

Cash & equivalents stood at $736.01B at the end of Q3 FY2026, up 58775.5% from a year earlier and up 84110.8% from the prior quarter. Over 3 fiscal years it compounded at +21.9% a year.

Context

  • Cash & equivalents amounted to 6.4% of total assets at the end of Q3 FY2026, down 10.1 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +58775.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$736.01B+84110.8% QoQ
Last fiscal yearDec 2025
$1.31B+39.1% YoY
Year agoSep 2025
$1.25B+58775.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58775.5%——
1 year+39.1%——
3-year CAGR+21.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
1.31B USD
Year-over-year change
+39.1%
4-year CAGR
+22.2%

Cash & Equivalents vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +58775.5% is the highest of 11, against a peer median of -3.2%.
  • Cash & equivalents amounts to 6.4% of total assets for BMRN, versus a peer median of 20.2%.
BMRN Competitors
Cash & Equivalents for BMRN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$736.01B USD+58775.5%+21.9%6.4%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$1.71B USD+53.4%+24.1%30.7%
PTCTPTC Therapeutics, Inc.Jun 2026$1.05B USD+3.2%+52.1%32.3%
ASNDAscendis Pharma A/SSep 2026€964.36M EUR+78.9%+11.5%39.7%
BBIOBridgeBio Pharma, Inc.Jun 2026$677.91M USD-9.5%+14.8%55.7%
INSMInsmed IncorporatedJun 2026$544.77M USD-57.6%-22.0%25.9%
IONSIonis Pharmaceuticals, Inc.Sep 2026$296.3M USD-12.4%+10.4%10.2%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$175M USD+37.7%+48.3%13.5%
TVTXTravere Therapeutics, Inc.Sep 2026$123.54M USD+11.4%+14.7%14.6%
PHARPharming Group N.V.Mar 2026$53.1M USD-11.6%-11.0%10.9%
VRTXVertex Pharmaceuticals IncorporatedSep 2026$0 USD-100.0%-21.5%0.0%
Peer median (excluding BMRN) —-3.2%+13.1%20.2%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents587.28M724.53M755.13M942.84M1.31B
Short-term Investments426.6M567.01M318.68M194.86M248.93M
Net Receivables373.4M461.32M633.7M660.54M908.21M
Inventory776.67M894.08M1.11B1.23B1.3B
Other Current Assets110.44M104.52M141.39M201.53M185.78M
Total Current Assets2.27B2.75B2.96B3.23B3.95B
Property, Plant & Equipment (Net)1.04B1.07B1.07B1.04B952.51M
Goodwill196.2M196.2M196.2M196.2M196.2M
Intangible Assets388.65M338.57M294.7M255.28M213.84M
Long-term Investments507.79M333.84M611.14M521.24M498.21M
Tax Assets1.45B1.51B1.55B1.49B1.51B
Other Non-current Assets152.12M176.24M171.54M251.39M277.05M
Total Non-current Assets3.73B3.62B3.89B3.76B3.64B
Total Assets6B6.38B6.84B6.99B7.59B
Account Payables199.68M231.24M315.51M235.4M312.77M
Short-term Debt00493.88M23.07M8.69M
Tax Payables1.21M16.21M2.65M12.57M0
Deferred Revenue6.96M711K4.62M1.37M0
Other Current Liabilities258.94M236.1M234.92M132.07M210.72M
Total Current Liabilities546.5M588.88M1.18B606.99M759.03M
Long-term Debt1.08B1.08B593.1M595.14M597.18M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities113.53M100.02M119.94M97.57M113.8M
Total Non-current Liabilities1.19B1.18B713.03M723.96M747.99M
Total Liabilities1.74B1.77B1.89B1.33B1.51B
Common Stock184K186K189K191K192K
Retained Earnings(930.76M)(789.2M)(621.55M)(194.7M)154.21M
Accumulated OCI14.43M(3.87M)(28.79M)61.65M(13.47M)
Other Stockholders Equity(9.69M)(8.86M)(9.86M)(11.23M)(10.51M)
Minority Interest00000
Total Equity4.27B4.6B4.95B5.66B6.09B
Total Debt1.09B1.09B1.1B649.47M642.87M
Net Debt502.27M368.86M340.62M(293.38M)(668.81M)

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.